Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.Applied Nanoscience Inc. (ANI) (PINKSHEETS:APNN), a nanotechnology-based filtration company, today issued a progress report to its investors relating to progress in commercializing the disposable NanoFense™ Protective Face Mask, designed to offer superior protection against a broad spectrum of harmful virus, bacteria and fungi.Amarin Corp. (NASDAQ:AMRN), a clinical stage pharmaceutical company with R&D operations based in Mystic, Conn., has joined SAFE-BioPharma Association, the non-profit association that created and manages the global SAFE-BioPharma® digital identity and signature standard for the pharmaceutical and healthcare industries.Adolor Corporation (Nasdaq:ADLR) announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD).Abbott (NYSE:ABT) announced a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today.CellCyte Genetics Corporation (OTC:CCYG) announced the appointment of Dr. Douglas Cerretti as Chief Science Officer and Director of Business Development effective November 1, 2009.DuPont (NYSE:DD) and BSES Limited announced a research, development and commercialization alliance to improve productivity and use of sugarcane varieties.Edwards Lifesciences Corporation (NYSE:EW), the global leader in the science of heart valves and hemodynamic monitoring, announced The Edwards Lifesciences Fund is granting $1.8 million to 107 nonprofit organizations as part of its fifth annual grant cycle. This fund is a donor-advised fund of the Vanguard Charitable Endowment Program.Inovio Biomedical Corporation (NYSE:INO), a leader in DNA vaccine design, development and delivery, announced the company will highlight its technology at two worldwide vaccine conferences next week. Dr. David Weiner, Chair of Inovio’s Scientific Advisory Board, and Niranjan Sardesai, Senior Vice President, SVP, Research and Development will speak on Inovio’s DNA vaccine development.Inhibitex, Inc. (Nasdaq:INHX), announced Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City on Tuesday, November 17, 2009 at 1:40 p.m. Eastern Time.Luna Innovations Incorporated (NASDAQ:LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the quarter ended September 30, 2009.Medtronic, Inc. (NYSE:MDT) announced the kick-off of an educational campaign aimed at raising awareness among women of overactive bladder (OAB), a serious condition that can severely impact patients’ lives.Mach One Corporation (OTC:MNCN), a rapidly growing, innovative, global wellness solutions company, announced it has completed the first tranche of its investment in PanTheryx, Inc., as stipulated in a recent Letter of Understanding signed in August 2009.Millipore Corporation (NYSE:MIL) a leading provider of technologies, tools and services for the global life science industry has been named “Corporate Citizen of the Year” by the New England Clean Energy Council.NeoGenomics, Inc. (OTC:NGNM) announced it will present at the Lazard Capital Markets 6th Annual Healthcare Conference being held November 17-18, 2009, at the St. Regis, New York Hotel in New York City.Nutra Pharma Corp. (OTC:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever.Nile Therapeutics, Inc. (NASDAQ:NLTX), a company focused on the development of novel therapeutics for heart failure patients, announced its third quarter financial results for 2009.For the fiscal year ending June 30th, 2009, PD-Rx (Pink Sheets: PDRX) set record sales of $26.9 million over last year's sales figures of $26.4 million, reporting a net increase in sales of $493,230.PharmAthene, Inc. (NYSE:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, reported financial and operational results for the third quarter and nine months ended September 30, 2009.Repros Therapeutics Inc. (Nasdaq:RPRX) announced it has elected Dr. Jaye Thompson to its Board of Directors, and as a member of the Board’s Audit Committee, effective immediately.Shire plc (Nasdaq:SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®.In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.ULURU Inc. (NYSE:ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, announced it has entered into definitive agreements to sell 10,714,467 shares of its common stock at a price per share of $0.14 pursuant to a registered direct offering to institutional investors, resulting in gross proceeds of approximately $1.5 million.
InfuSystem Holdings, Inc. (INHI), which operates in the same business as medical device makers like Boston Scientific Corporation (BSX) and Edwards Lifesciences Corporation (EW), held its third quarter conference call on Monday where it outlined its quarterly performance and some impressive growth initiatives going forward.
Investors can listen to a conference call replay by clicking here:
[...]
Analysts were expecting Greatbatch, Inc. (GB) [Chart - News - Analysis] to report earnings of $0.36 for last quarter, but GB missed expectations with actual earnings of $0.32---4 cents below the consensus estimate. GB also issued earnings guidance for next quarter that is below current analyst expectations.
If you compare last quarter's earnings to the $0.44 the company made per share during the same quarter a year ago, you can see that GB’s earnings are down this year.
{loadposition link_newslink1}
{loadposition livevideopromo}
{loadposition homeaccordion2}
{loadposition contentad}
Also, if you compare GB's 14.00% projected earnings-per-share (EPS) growth rate for the next five years with the projected EPS growth rate of 13.44% for the Medical Appliances & Equipment industry as a whole during that same time frame, you can see that analysts expect GB to outperform the industry in the future---which is a good sign for the stock.
Drilling down a little deeper into the Medical Appliances & Equipment industry, you can see how analysts believe GB will stack up against some of the other stocks in the industry, like Edwards Lifesciences Corp. (EW) [Chart - News - Analysis] and Zimmer Holdings Inc. (ZMH) [Chart - News - Analysis], in the future. Analysts believe EW's earnings are going to grow at a rate of 16.24% while ZMH's earnings are going to grow at a rate of 9.69%.
Earnings season can be a volatile time in the stock market. Check out these videos and articles to be better prepared to take advantage of the large price moves that tend to accompany earnings announcements.
ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents.
Total revenues for the reported quarter were $18.8 million, increasing 17.3% year over year. Excluding an unfavorable foreign currency translation (FX), total revenues [...]
ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents.
Total revenues for the reported quarter were $18.8 million, increasing 17.3% year over year. Excluding an unfavorable foreign currency translation (FX), total revenues increased 19.4% year over year. Growth was broad-based across its major business segments.
Heart valve therapy revenues increased 20.5% year over year to $14.2 million. In this segment, Mechanical valve revenues increased 10% year over year to $11.6 million. This was due to higher demand for the ATS Open Pivot Mechanical Heart Valve in Asia and success from the recent launch of the AP360 valve in Japan.
Tissue valve revenues were $1.4 million, compared to $0.3 million in the year-ago quarter. Heart valve repair revenues increased 29% year over year to $1.2 million. ATS Medical received U.S. Food and Drug Administration (FDA) approval and also completed the first implant of a new ATS Simulus semi-rigid band in the reported quarter.
Cryoablation revenues increased 12% year over year to $4.5 million. The company launched the new ATS CryoMaze 10-S Surgical Cryoablation Probe in the U.S. in the third quarter. Furthermore, it received the CE Mark approval to market the new ATS CryoMaze 10-S Probe in Europe in Oct. 2009 and expects to launch the product there in the fourth quarter.
Gross margin in the quarter increased 380 basis points (bps) year over year to 62.9%. The company’s strong cost-cutting initiatives helped it in lowering the operating and net loss margins. Operating loss margin improved 1,400 bps year over year to a negative 3.1%. Net loss margin improved 1,810 bps year over year to a negative 5.2%.
ATS Medical ended the quarter with cash and short-term investments of roughly $12.1 million. The company had no outstanding debt at the end of the quarter and generated positive cash flow of approximately $0.8 million in the third quarter.
ATS Medical reaffirmed its revenue guidance of $77 to $79 million for full fiscal year 2009. The company also expects to generate net income in the fourth quarter of 2009.
Market Close Live for Monday 9/11/06
Get ready for the week with a 15-minute recap of the days action along with a look ahead as Matt McCall of "Market Close Live" breaks down the markets.
Matt discusses several ETFS and Stocks that were generated by the PFG Breakout Scan and have shown relative strength.
Find out what pattern was formed today on the GOLD futures chart and what it means for the future.
STOCKS/ETFS Mentioned: MTD, HUM, PIC, MET, RGA, EW, CBS, ICF, RTH, GDX, GLD, IPS, NSS, FSL
"Market Close Live" IS NOW available as a "PODCAST" for those who have MP3 player. If you are interested in learning how to get "Market Close Live" on your MP3 player please email info@pennfinancialgroup.com.
***** TO GET YOUR STOCK/MARKET QUESTIONS ANSWERED YOU CAN EMAIL THEM TO: info@pennfinancialgroup.com
All News |
Breaking News |
Featured Stories